Literature DB >> 36211612

Bilateral upper extremity myositis after COVID-19 vaccination.

Ivan Rodrigues Barros Godoy1, Tatiane Cantarelli Rodrigues1, Abdalla Youssef Skaf1.   

Abstract

Vaccination adverse reactions are common and usually are represented by transitory pain and edema. We present a case of bilateral muscle edema involving shoulders and arms due to myositis following COVID-19 vaccination, and focus on the imaging findings to differentiate with other diagnosis such as infection and tumors.
© 2022 The Authors. Published by the British Institute of Radiology.

Entities:  

Year:  2022        PMID: 36211612      PMCID: PMC9518739          DOI: 10.1259/bjrcr.20220002

Source DB:  PubMed          Journal:  BJR Case Rep        ISSN: 2055-7159


Case presentation

A 64-year-old healthy female with no prior SARS-CoV-2 infection presented with bilateral shoulder and arm pain and weakness. The patient reported no unusual movement or trauma previous to the onset of symptoms. Pain and weakness started 15 days after the first dose of COVID-19 vaccine (adenovirus-based Covishield – Oxford/Astrazeneca). The healthcare worker responsible for the application did not report any complication during the injection. During physical examination, there were no signs of skin erythema, swelling, or fever.

Investigation

Magnetic resonance (MR) of shoulders and arms was performed to evaluate arm pain and weakness demonstrating diffuse and bilateral edema involving the trapezius, deltoid, rotator cuff, biceps and triceps muscles, with no muscle tear of abscess (Figure 1).
Figure 1.

Right (a) and left (b) coronal T2 fat-saturated shoulder MR images demonstrating trapezius, deltoid, and rotator cuff muscle edema (white stars). Similar findings were observed in axial (c, d) coronal T2 fat-saturated shoulder MR images and coronal (e, f) arm MR imaging involving also biceps and triceps muscles.

Right (a) and left (b) coronal T2 fat-saturated shoulder MR images demonstrating trapezius, deltoid, and rotator cuff muscle edema (white stars). Similar findings were observed in axial (c, d) coronal T2 fat-saturated shoulder MR images and coronal (e, f) arm MR imaging involving also biceps and triceps muscles.

Differential diagnosis

Inflammatory myositis was the leading diagnosis for this case. Other potential causes of upper limb weakness such as cervical spine disc herniation, myelopathy, infection, tumors, and shoulder/arm tendinopathy were less likely given the interval appearance and imaging characteristics.

Treatment

Patient had progressive upper extremity weakness and dysphagia and was hospitalized. Myositis was managed with rest, corticoid, and immunosuppressant therapy associated with physiotherapy.

Outcome and follow-up

After 3 months of hospitalization, the patient regained muscle strength and was discharged. Follow-up imaging was performed 4 months after the onset of the symptoms and demonstrated bilateral muscle edema reduction without other complications (Figure 2).
Figure 2.

Follow-up MR imaging demonstrating reduction of muscle edema (white stars) after 4 months.

Follow-up MR imaging demonstrating reduction of muscle edema (white stars) after 4 months. Adverse reactions following vaccination are frequent and usually are characterized by transient pain, edema, and tenderness at the site of the injection.[1] Other systemic events were described after Covishield vaccination such as fatigue, headache, body pain, fever, gastrointestinal side-effects, and even vaccine-induced immune thrombotic thrombocytopenia, raising concern for clinicians to be aware of the evaluation of those conditions. Reports identified myositis ossificans,[1] deltoid myositis,[2] and subacromial-subdeltoid bursitis after COVID-19 vaccination,[3] demonstrating immune response drawn by the intramuscular injected antigen. The muscular inflammatory response may be related to the patient’s immune response to the vaccine components.[4,5] In this report, we did not perform a muscle biopsy and the temporal link between symptoms and vaccination procedure suggests diagnosis of COVID-19 vaccine-related myositis as the cause of symptoms. Authors considered that toxic myopathy may also be a cause for reported pain, edema, and weakness. Although neuromuscular presentations of COVID-19 infection have been reported,[6][7]bilateral upper extremity diffuse muscle edema after COVID-19 vaccination was not described before.

Learning points

The case presented illustrates a bilateral upper extremity myositis involving shoulders and arms following COVID-19 vaccination. Vaccination adverse reactions are common and usually are represented by transitory pain and edema. Imaging findings are paramount to differentiate myositis with other diagnosis and key to follow-up after treatment.
  7 in total

Review 1.  Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations.

Authors:  L H Martín Arias; R Sanz Fadrique; M Sáinz Gil; M E Salgueiro-Vazquez
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

Review 2.  Drug-related myopathies of which the clinician should be aware.

Authors:  Ritu Valiyil; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 3.  Toxic and drug-induced myopathies.

Authors:  M C Dalakas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-08       Impact factor: 10.154

4.  COVID-19 vaccine-related myositis.

Authors:  D J Theodorou; S J Theodorou; A Axiotis; M Gianniki; N Tsifetaki
Journal:  QJM       Date:  2021-02-27

5.  Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA).

Authors:  Tatiane Cantarelli Rodrigues; Pedro Filgueiras Hidalgo; Abdalla Youssef Skaf; Aline Serfaty
Journal:  Skeletal Radiol       Date:  2021-05-04       Impact factor: 2.199

6.  Myositis ossificans following COVID-19 vaccination.

Authors:  Ivan R B Godoy; Tatiane Cantarelli Rodrigues; Abdalla Skaf
Journal:  QJM       Date:  2021-06-09

Review 7.  Neuromuscular presentations in patients with COVID-19.

Authors:  Vimal Kumar Paliwal; Ravindra Kumar Garg; Ankit Gupta; Nidhi Tejan
Journal:  Neurol Sci       Date:  2020-09-15       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.